Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)

Abstract Introduction Avelumab, pembrolizumab, and enfortumab vedotin (EV) demonstrated efficacy in mUC following platinum-based chemotherapy. However, real-world data in patients with urothelial carcinoma with squamous differentiation (UCSD) are limited. The aim of this study is to assess the real-...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Veronica Mollica, Francesco Massari, Kazutoshi Fujita, Patrizia Giannatempo, Enrique Grande, Thomas Büttner, Maria T. Bourlon, Tarek Taha, Wataru Fukuokaya, Zin W. Myint, Renate Pichler, Kirstin Binz, Javier Molina‑Cerrillo, Jindrich Kopecky, Alfonso Gómez de Liaño, Jakub Kucharz, Ondřej Fiala, Marc R. Matrana, Ray Manneh Kopp, Mattia Alberto Di Civita, Anca Zgura, Jawaher Ansari, Randi Kihnel, Francesca De Felice, Martín Angel, Fernando Sabino M. Monteiro, Andrey Soares, Yuksel Urun, Sebastiano Buti, Daniele Santini, Matteo Santoni
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Springer 2026-03-01
Saila:	Cancer Immunology, Immunotherapy
Gaiak:	Avelumab Enfortumab Vedotin Immunotherapy NCT05290038 Pembrolizumab Squamous differentiation
Sarrera elektronikoa:	https://doi.org/10.1007/s00262-026-04328-9
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!